Accelerated Approval

How Accelerated Approval Works

Eligibility Criteria

Requirement	Description
Serious condition	Disease that has substantial impact on daily functioning or is life-threatening
Unmet medical need	No adequate existing therapies or improvement over available treatments
Surrogate endpoint	Reasonably likely to predict clinical benefit
Post-marketing commitment	Sponsor agrees to conduct confirmatory trials

The Approval Process

1. Pre-submission meeting - Discuss surrogate endpoint acceptability with FDA
2. Clinical trials - Demonstrate effect on surrogate endpoint
3. NDA/BLA submission - Submit data with proposed confirmatory studies
4. FDA review - Evaluate surrogate endpoint validity and benefit-risk
5. Conditional approval - Approved with required post-marketing studies
6. Confirmatory trials - Verify clinical benefit in additional studies

Surrogate Endpoints in Accelerated Approval

What Qualifies as a Surrogate

A surrogate endpoint must be:

• Measurable in a shorter timeframe than clinical outcomes
• Reasonably likely to predict the clinical benefit
• Validated by scientific evidence linking it to outcomes

Common Surrogate Endpoints

Therapeutic Area	Surrogate Endpoint	Clinical Outcome
Cardiovascular	LDL cholesterol reduction	Heart attack, stroke
Diabetes	HbA1c reduction	Diabetic complications
Oncology	Tumor shrinkage	Survival
HIV	CD4 count/viral load	AIDS progression

Relevance to Metabolic Therapies

GLP-1 Agonist Pathway

GLP-1 receptor agonists like semaglutide followed traditional approval pathways using HbA1c as a well-established surrogate endpoint for diabetes. However, newer indications have utilized various approval mechanisms:

Drug	Indication	Pathway
Semaglutide (Wegovy)	Obesity	Traditional (weight loss as primary endpoint)
Tirzepatide (Zepbound)	Obesity	Traditional approval
Future cardiovascular claims	CV risk reduction	Required outcome trials

Why Understanding Approval Pathways Matters

• Strength of evidence - Traditional approval has more robust efficacy data
• Post-marketing requirements - Accelerated approval drugs need ongoing monitoring
• Potential withdrawal - Drugs may be removed if confirmatory trials fail
• Insurance coverage - Payers may restrict coverage pending confirmatory data

Post-Marketing Requirements

Confirmatory Trial Obligations

Sponsors receiving accelerated approval must:

• Conduct studies verifying clinical benefit
• Complete trials with due diligence
• Submit results to FDA for review
• Potentially face withdrawal if benefit not confirmed

Recent FDA Enforcement

Action	Situation
Voluntary withdrawal	Sponsor removes drug when trials fail
FDA withdrawal	Mandatory removal for unconfirmed benefit
Conversion to traditional	Confirmatory trials successful
Label modification	Indication narrowed based on new data

Benefits and Limitations

Advantages

• Faster patient access to promising therapies (often 2-3 years earlier)
• Treatment options for serious conditions with few alternatives
• Incentivizes development for difficult-to-treat diseases
• Real-world evidence generation during post-marketing period

Concerns

• Approval based on surrogate, not proven clinical benefit
• Confirmatory trials may take years or fail to confirm benefit
• Potential exposure of patients to ineffective therapies
• Healthcare system costs for unproven treatments

Frequently Asked Questions

How is accelerated approval different from priority review?

Accelerated approval changes the evidence standard (surrogate vs clinical endpoints), while priority review shortens the FDA review timeline without changing evidence requirements. A drug can receive both designations simultaneously.

Can an accelerated approval be revoked?

Yes. If post-marketing confirmatory studies fail to verify clinical benefit, or if the sponsor fails to conduct required studies with due diligence, FDA can initiate proceedings to withdraw approval. This has happened with several oncology drugs.

Should I trust a drug with accelerated approval?

Accelerated approval indicates the FDA believes the drug is likely to provide clinical benefit based on surrogate data, and that the benefit-risk is favorable for serious conditions. However, the clinical benefit remains to be confirmed. Discuss the strength of evidence with your healthcare provider.